Definition of isolated systolic hypertension (ISH) according to JNC-VI (1) and 1999 WHO/ISH (2): systolic blood pressure (SBP) ≥140 mm Hg, diastolic blood pressure <90 mmHg. Accordingly, the different grades of ISH are defined as follows:
ISH as cardiovascular risk
There are little data on the prevalence of ISH, using the latest definition of ≥140/<90 mm Hg. Prevalence of ISH (old definition) increases with age (Table 2 ). It becomes the most common type of hypertension in the elderly, and it is the most prevalent type of untreated hypertension among older people over 60 yrs of age (6).
Table 2. Prevalence of ISH (old definition of ≥ ≥160/<90 mm Hg)
According to the cumulative 24-year data from the Framingham Study (also using the old definition) the incidence of ISH is high both in women (533/1000) and in men (418/1000) over the age of 65 years. ISH was the most common type of diagnosed hypertension (57.4% in men, 65.1% in women) at the age over 65 yrs (7) . Subjects with Grade-1 ISH (old definition: borderline ISH) were found to be at increased risk of progression to definite (Grade 2) hypertension and the development of cardiovascular disease (7) . Several studies have demonstrated the increased risk for cardio-or cerebrovascular diseases, and death (including sudden death) of patients with ISH. ISH increases cardiovascular morbidity and all-cause mortality twofold or more and triples cardiovascular mortality. In the MRFIT study of 316 099 men it was found that systolic blood pressure was a stronger predictor of outcome than diastolic blood pressure, and an excess risk of cardiovascular diseases exists in subjects with stage I (borderline) ISH (8, 9, 10, 11, 12) . Untreated ISH patients showed a high prevalence of LVH with a concentric remodelling (13) , which has been shown to have a poor cardiovascular prognosis (14) . The meta-analysis of 8 outcome trials involving 15,693 patients with ISH and a follow-up period of 3.8 years (median) showed that the relative hazard rates associated with a 10 mm Hg higher initial systolic blood pressure were 1.26 for total mortality, 1.22 for stroke, but only 1.07 for coronary events. Independent of systolic blood pressure, diastolic blood pressure was inversely correlated with total mortality, stressing the role of pulse pressure as risk factor (21) .
Treatment benefits
Randomised clinical trials provided compelling evidence that treatment of ISH results in significant benefits. The landmark trial of Systolic Hypertension in the Elderly Program (SHEP) in 4716 patients first proved the benefit on CV morbidity and mortality of antihypertensive treatment with chlorthalidone (with the option of adding atenolol or reserpine). Non-fatal stroke was reduced by 37 %, non-fatal myocardial infarction by 33 %, and left ventricular failure by 54 %. There were strong trends to decrease in transient ischemic attacks (25 %) , and in total (13 %), cardiovascular (20 %), cerebrovascular (29 %) and coronary (20 %) mortality (15) . This trial also pointed out that serum uric acid independently predicts cardiovascular events in patients with ISH. These patients experienced the same benefit from diuretic-based treatment as those with low baseline serum uric acid levels (16) . The Systolic Hypertension in Europe (Syst-Eur) was the first large (4695 patients with ISH) study of the effect of a longer-acting calcium antagonist, nitrendipine (with optional add-on enalapril and/or hydrochlorothiazide), on long-term morbidity and mortality risks. Total strokes were reduced by 42 % (17). In the Syst-Eur trial the rate of vascular dementia was also reduced by 50 % (18), while it was not changed by the chlorthalidone-based therapy in the SHEP (16), therefore a specific neuroprotecive effect of dihydropyridine-type calcium antagonist, nitrendipine was hypothesized. The Syst-China trial confirmed the beneficial effect of nitrendipine in patients with ISH as it reduced total strokes by 38 %, stroke mortality by 58 %, all-cause mortality by 39 %, cardiovascular mortality by 39 %, fatal and non-fatal CV events by 37 % (19) . Subgroup analysis of the recently published INSIGHT trial showed that patients with ISH were slightly more responsive than ordinary hypertension to treatment by long-acting nifedipine-GITS as significantly less patients required addition of a second drug. An important result from this study showed that patients with ISH whose diastolic blood pressure significantly decreased with increasing therapy were smokers with existing evidence of atherosclerosis (20). Staessen's meta-analysis showed that active treatment reduced total mortality by 13 %, cardiovascular mortality by 18 %, all cardiovascular complications by 26 %, stroke by 30 % and coronary events by 23 %. The absolute benefit was larger in men, in patients aged 70 yrs. or more, and in those with previous cardiovascular complications or wider pulse pressure. Therapy prevented strokes more effectively than coronary events (21) .
Efficacy trials showed that thiazide-based treatment is superior to beta-blockers for reduction of blood pressure and prevention of cardiovascular complications (22, 23, 24) . Recent trials with newer antihypertensive agents, such as ACEinhibitors, angiotensin AT1 receptor antagonists have also demonstrated improved blood pressure control of patients with ISH (25, 26) . The new class of antihypertensive drugs, the vasopeptidase inhibitors such as omapatrilate, may have a particular importance in the treatment of patients with ISH because its effect on systolic blood pressure is greater than on diastolic blood pressure (27) .
Guidelines for management of ISH: Lifestyle modifications (physical exercise, reduction in salt intake, weight reduction in obese patients, stop smoking) are advised as first-line therapy for the patients with ISH (1, 2). The recommended target systolic blood pressure is to or below 140 mm Hg (with a possible interim goal to below 160 mm Hg). If lifestyle modifications fail to reach the target, drug therapy is advised to control blood pressure. Diuretics and long-acting dihydropyridine-type calcium antagonists are considered first-line treatment of patients with ISH. ACE-inhibitors, angiotensin AT1 receptor antagonists are also effective drugs for ISH, but there are less data available regarding their effects on cardiovascular mortality and morbidity in patients with ISH. The results of several ongoing trials are expected to provide further information on possible additional advantage of newer promising agents.
